PhaseRx (NASDAQ:PZRX) last posted its quarterly earnings results on Thursday, August 10th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.09). On average, analysts expect PhaseRx to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Shares of PhaseRx, Inc. (NASDAQ PZRX) opened at 0.6399 on Monday. PhaseRx, Inc. has a 52-week low of $0.54 and a 52-week high of $3.30. The firm’s market capitalization is $7.48 million. The firm has a 50-day moving average of $0.88 and a 200 day moving average of $0.88.
Separately, Laidlaw lowered shares of PhaseRx from a “buy” rating to a “neutral” rating in a research report on Friday, October 13th.
A hedge fund recently raised its stake in PhaseRx stock. Vanguard Group Inc. increased its holdings in shares of PhaseRx, Inc. (NASDAQ:PZRX) by 4.0% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 142,182 shares of the company’s stock after acquiring an additional 5,500 shares during the quarter. Vanguard Group Inc. owned about 1.22% of PhaseRx worth $135,000 as of its most recent filing with the SEC. 2.38% of the stock is owned by hedge funds and other institutional investors.
PhaseRx, Inc is a biopharmaceutical company developing a portfolio of mRNA products to correct life-threatening inherited liver diseases in children. The Company’s initial product development focus is on urea cycle disorders, a group of rare genetic diseases that generally present before the age of 12 and are characterized by the body’s inability to remove ammonia from the blood.
What are top analysts saying about PhaseRx Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for PhaseRx Inc. and related companies.